Studies have shown that a loss of expression of ADAM23 gene and its correlation with promoter methylation has been frequently reported in breast cancer, brain cancer, and pancreatic cancer [42, 43]. This evidence concerns the gene ADAM23 and familial pancreatic carcinoma.